Compare Amphastar Pharmaceuticals Inc (AMPH) vs CubeSmart (CUBE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs CubeSmart — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while CubeSmart trades at $40.16 (market cap $9.10B). The key difference: CubeSmart is far larger — about 11× Amphastar Pharmaceuticals Inc's market cap, and CubeSmart pays a 5.27% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | CUBE | |
|---|---|---|
Market Cap | $826.08M | $9.10B |
Sector | Health | Real Estate |
52-Week High | $30.81 | $42.34 |
52-Week Low | $16.87 | $35.36 |
Enterprise Value | $1.22B | $12.60B |
Dividend Yield | — | 5.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
CubeSmart (CUBE) trades at $40.19, up 1.01% with a bearish technical signal despite recent earnings beats. The REIT maintains strong profitability with 28.93% net margins and offers a 5.3% dividend yield. Analyst consensus shows mixed sentiment with 41% buy ratings but a $43.86 price target suggesting 9% upside. Recent news highlights Q2 2026 earnings anticipation on July 30, 2026, while institutional investors have been trimming positions.
The stock presents value with reasonable valuation multiples (P/E 28.1, P/S 8.13) and consistent cash flow generation, though high debt levels and interest rate sensitivity pose risks. Near-term performance will depend on Q2 earnings results and macroeconomic conditions affecting the self-storage sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About CubeSmart
CubeSmart is a real estate investment trust that acquires, owns, and manages self-storage facilities throughout the United States. The company's real estate portfolio is composed of buildings with numerous enclosed storage areas for both residential and commercial customers to rent mainly on a month-by-month basis. Most of CubeSmart's facilities are located in Florida, Texas, California, New York, and Illinois. Cumulatively, these states account for both the majority of the square footage in the company's real estate portfolio and the majority of its revenue. CubeSmart derives nearly all of its revenue from rental income from tenants utilizing its storage facilities.
Read more on CUBE →
